プレロードは,心筋動脈不全と無関係にトロポニンIの分解を誘導する
J Feng1, B J Schaus, J A Fallavollita
1Department of Surgery, University at Buffalo, NY 14214, USA.
Circulation
|April 25, 2001
まとめ
前負荷はイシュケミアではなく,カルパイン活性化によるトロポニンI (TnI) の分解を引き起こします. カルパインを遮断すると,心臓の機能が改善され,TnIの分解が防止され,心臓疾患の新たな治療目標が示唆されます.
科学分野:
- 心臓病学 心臓病学
- バイオケミストリー バイオケミストリー
- 生理学 生理学とは
背景:
- グローバル・イシュケミアはトロポニンI (TnI) を分解するが,地域性イシュケミアはそうではない.
- この違いは,前負荷誘発タンパク質分解の異なるレベルから生じる可能性があります.
研究 の 目的:
- トロポニンI (TnI) の分解におけるプレロードの役割を調査する.
- カルパインの活性化がTnIタンパク質分解を媒介するかどうかを判断する.
- TnIの退化防止が心筋機能に与える影響を評価する.
主な方法:
- 孤立したネズミの心臓は,制御されたプレロードレベルで注入されました.
- トロポニンI (TnI) の分解は,ウエスタン・ブロッティングを用いて定量化されました.
- カルペプチンを用いてカルパインの活性化が抑制されました.
- 心臓の機能を評価するために,左心室内静脈圧を測定した.
主要な成果:
- プレロードの増加により,TnIの劣化が顕著に誘発され,帯域強度の変化が示されました.
- カルペプチンによるカルパイン抑制は,TnIの分解を完全に阻害し,心臓の機能を改善しました.
- イシュケミアの後のプレロードの上昇を防ぐことによって,TnIの劣化も防ぐことができました.
結論:
- カルパイン媒介のトロポニンI (TnI) タンパク質分解は,前負荷の上昇によって引き起こされ,イシュケミアそのものではない.
- この退廃は,心筋麻痺とは無関係に起こる可能性があります.
- プレロードによって引き起こされるTnIの劣化は,心臓機能に長期的な悪影響を及ぼす可能性があります.
関連する概念動画
01:26Heart Failure Drugs: Inotropic Agents
2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
2.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
01:22Heart Failure Drugs: β-Blockers
2.9K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.9K
01:26Imbalances in Cardiac Output
3.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
3.3K
01:26Pneumothorax-I
2.2K
A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
2.2K
01:27Heart Failure I: Introduction
2.0K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
2.0K